Ocular Therapeutix (OCUL) Cash from Investing Activities (2013 - 2026)

Ocular Therapeutix's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$4.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 141.18% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$14.6 million, a 392.55% decrease from a year earlier, with the FY2025 full-year figure at -$11.9 million, down 822.36% from the prior year.
• Cash from Investing Activities retreated to -$4.7 million in Q1 2026 per OCUL's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$89000.0 in Q3 2024 and bottomed at -$6.0 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is -$794000.0 (2022), against an average of -$1.6 million.
• Across the five-year window, Cash from Investing Activities jumped 92.45% in 2024 and sank 6633.71% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$2.2 million in 2022, then jumped by 78.65% to -$459000.0 in 2023, then surged by 55.99% to -$202000.0 in 2024, then tumbled by 1305.45% to -$2.8 million in 2025, then sank by 64.21% to -$4.7 million in 2026.
• Per Business Quant, the three latest OCUL Cash from Investing Activities figures stand at -$4.7 million (Q1 2026), -$2.8 million (Q4 2025), and -$6.0 million (Q3 2025).